Technology Transfer











CWC Home

Cornell University
314 Day Hall
Ithaca, New York
14853-2801

P: 607.255.7200
E: VP Research




BZL Biologics entered into a sublicense agreement with Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) to develop and commercialize antibody-based therapeutics targeting Prostate Specific Membrane Antigen (PSMA). BZL is a privately owned company that licensed the antibody therapeutics from the Cornell Research Foundation, Inc. (CRF). The technology was developed in the laboratory of Neil Bander, Bernard and Josephine Chaus Professor of Urological Oncology and Professor of Urology at the Joan and Sanford I. Weill Medical College of Cornell University. PSMA is believed to be the best-established, prostate-associated, cell surface molecule currently known. It is expressed by virtually every prostate tumor (both primary and metastatic) and the level of expression increases with tumor progression.

[Download PDF (80k)]




Research in Progress

01


Outreach

03


Economic Development

05


Undergraduate Research

02

Technology Transfer

04

Research in Focus

06

© 2002 by the Office of the Vice Provost for Research [OVPR], Cornell University